PharmD Capital Trading with PharmD_KS

PharmD Capital Trading with PharmD_KS

Share this post

PharmD Capital Trading with PharmD_KS
PharmD Capital Trading with PharmD_KS
Market Analysis and Trades for 2/28
Copy link
Facebook
Email
Notes
More

Market Analysis and Trades for 2/28

PharmD_KS's avatar
PharmD_KS
Feb 27, 2025
∙ Paid
23

Share this post

PharmD Capital Trading with PharmD_KS
PharmD Capital Trading with PharmD_KS
Market Analysis and Trades for 2/28
Copy link
Facebook
Email
Notes
More
3
1
Share

If you are looking to join the Discord (now separate from the newsletter) please see here: JOIN THE DISCORD Please email help@pharmdcapital.com if there are any technical issues. Plans/levels will be posted in the Discord so there is no reason to subscribe to both

The weekly post and for SPY 0.00%↑ and QQQ 0.00%↑ should be reviewed prior to this. Link to Market Analysis for The Week Ahead

The overnight session floated up after NVDA 0.00%↑ earnings and in my opinion, this was mostly a post event volatility float. I’ve mentioned a number of times recently that the market is primarily concerned with two things right now: the prospects of a recession and prospects of an earnings decline (the two are not unrelated).

This float up took us to the area we were looking to short on both ES and NQ. The ensuing selloff triggered a look below and fail of yesterday’s low on ES which was a long setup which resolved for 45+ handles (NQ offered a couple nice longs as well). However, sellers were able to cap the 5990.5-5994.5 range on ES and 160-171.5 on NQ and trigger the liquidation. From last night’s plan:

As we have come into a major spot, the focus of tonight’s plan will be the bare minimum reclaims buyers need to terminate this sell. I do this the same way that I map out the bear case when price is bullish. In this case, anything less than these reclaims, and we will be firmly short.

Paid content below and in the Discord.

Trading Doggy Style with PharmD_KS is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.

This post is for paid subscribers

Already a paid subscriber? Sign in
© 2025 PharmD_KS
Market data by Intrinio
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture

Share

Copy link
Facebook
Email
Notes
More